Positive market reaction to Apogee Therapeutics acquisition

AbbVie shares are experiencing a bullish movement of 2.76% today, driven by continued positive reactions to the company's acquisition of Apogee Therapeutics. This $10.8–$10.9 billion deal is aimed at enhancing AbbVie's immunology pipeline and long-term growth prospects. Investors are reassessing the updated expense outlook for 2026 associated with this acquisition, contributing to improved sentiment regarding AbbVie's future earnings and cash flow.